



Ain shams University
Faculty of Medicine
Tropical medicine department

**Correlation between Fib 4 score and Hematological adverse events
in patients with chronic hepatitis C virus infection under treatment
by Interferon based Triple therapy**

Thesis

Submitted for Partial Fulfillment of Master Degree

In Tropical Medicine

By:

ElSayed Gamal Mohammed

(M. B. B. CH)

Under Supervision Of

Prof. Dr. Mohamed Fawzy Montaser

Professor of Tropical medicine, former dean of Faculty of Medicine

Ain shams University

Prof. Dr. Samy Zaky Elsayed

Professor of Tropical medicine

Faculty of Medicine, Al-Azhar University (Damietta)

Dr. Mohamed Salaheldin Abd Elhamid

Lecturer of Tropical medicine

Faculty of Medicine, Ain shams University

2016

Acknowledgement

First and foremost, praise be to **ALLAH** for his help and generosity and giving me the force and confidence to finish this work.

I feel greatly indebted to **Prof. Dr. Mohamed Fawzy Montaser** Professor of Tropical medicine, former dean of Faculty of Medicine Ain shams University for the planning of this thesis and his continuous encouragement, guidance and supervision.

I would like to express my sincere gratitude and thanks to **Prof. Dr. Samy Zaky Elsayed** Professor of Tropical medicine Faculty of Medicine, Al-Azhar University (Damietta), for his kind supervision, encouragement and energetic help.

I would like, also, to record my deep thanks to **Dr. Mohamed Salaheldin Abd Elhamid** Lecturer of Tropical medicine Faculty of Medicine, Ain shams University, for his continuous guidance and supervision.

Finally I am deeply grateful to my family for their endless support and patience all over my life.

El Sayed Gamal Mohamed

2016

Contents

Title	page
<i>Introduction</i>	1
<i>Aim of The Work</i>	5
<i>Review of Literature</i>	6
<i>patients and methods</i>	04
<i>Results</i>	06
<i>Discussion</i>	97
<i>Summary</i>	88
<i>conclusions</i>	71
<i>Recommendations</i>	79
<i>References</i>	79
<i>protocol</i>	109
<i>Arabic summary</i>	

LIST OF Abbreviations

ALT	Alanine aminotransferase
AST	Aspartate aminotransferase.
b-DNA	branched DNA
CDC	Centers for Disease Control and Prevention
DAAs	Direct acting antiviral
DHS	Demographic Health Survey
EASL	European Association for the Study of the Liver.
EDHS	Egyptian Demographic Health Survey
EIA	Enzyme immunoassay
ELISA	Enzyme-linked immunosorbent assay.
ETR	End treatment response
EU	Europe
FDA	Food and drug administration
GBD	Global Burden of Diseases
GT	Genotypes
HAV	Hepatitis A virus
HBV	Hepatitis B virus
HCC	Hepatocellular carcinoma
HCV	Hepatitis C virus The nonstructural
HIV	Human immunodeficiency virus
HVR	Hypervariable regions
IFN	Interferon
INR	international normalized ratio
LB	liver biopsy
LIPA	Line probe assay.

MOH	Ministry of health
NLI	National Liver Institute.
NI_s	nucleoside inhibitors
NS	Nonstructural
NNI_s	nonnucleoside inhibitors
PAT	parenteral anti schistosomal therapy
PCR	Polymerase chain reaction.
PEG•IFN	PEGylated interferon
PLT_s	platelets count
PT	prothrombin time
RBV	ribavirin
RIBA	recombinant immunoblot assay
RVR	Rapid virological response
SOF	Sofosbuvir
SPP	signal peptide peptidase
SVR	Sustained virology response
TMA	Transcription- mediated amplification.
UTR	Un-translated regions
WHO	World Health Organization

List of figures

Figure no	Subject	page
Fig. (1)	Genome organization and polyprotein processing	8
Fig. (2)	Global hepatitis C virus genotype distribution	9
Fig. (3)	Current model of the HCV lifecycle	11
Fig. (4)	Anti-HCV seroprevalence by GBD region 2010	11
Fig. (5)	Prevalence of hepatitis C worldwide CDC 2012	11
Fig. (6)	Extrahepatic manifestations of HCV	11
Fig. (7)	Global Hepatitis C Virus and Egypt 2010	18
Fig. (8)	Sustained virology response to 48 wks. Of combination therapy in patients with hepatitis C virus genotype-4 using standard-dose PEGylated interferon and ribavirin (PEGylated-interferon-a 180 µg or PEGylated interferon-α2b 1.5 mg/kg and RBV 1-1.2 g/d).	11
Fig. (9)	Results of hepatitis C virus genotype-4 treatments with PEGylated interferon and ribavirin: 24 wks. vs 48 wks	13
Fig. (10)	Description of PCR results of studied patient	18
Fig. (11)	Association of RVR (PCR W 4) with Fib4.	35

Figure no	Subject	page
Fig. (12)	Association of ETR (PCR W12) with fib4.	52
Fig. (13)	Association of SVR with Fib4	31
Fig. (14)	Percentage of adverse effects due to treatment all over the follow up period	35
Fig. (15)	Comparison between patients with anemia and those without regarding to Fib4 Week 4.	55
Fig. (16)	Comparison between patients with leucopenia and those without regarding to Fib 4 in 4 th week	58
Fig. (17)	Comparison between patients with Neutropenia and those without regarding to Fib 4 in 4th week.	05

List of Tables

tables no	Subject	page
Tab. (1)	Hepatitis c virus genotype-4 percentage among infected patients in a selection of countries in Europe the Middle East, Africa, and India	14
Tab. (2)	Scoring systems for staging fibrosis assessed by liver biopsy	91
Tab. (3)	Common side-effects of combination PEG-IFN and ribavirin (RBV) treatment for chronic hepatitis C.	96
Tab. (4)	Uncommon and rare side-effects reported with combination IFN and RBV therapy for chronic hepatitis	99
Tab. (5)	description of demographic factors of studied patients	06
Tab. (6)	description of base line parameters of studied patients	09
Tab. (7)	Description of PCR results of studied patients	08
Tab. (8)	Association of RVR (PCR W 4) with baseline lab results, Fib 4 and demographic factors of studied patients.	07
Tab. (9)	Association of ETR (PCR W12) with baseline lab results, Fib4 and demographic factors of studied patients	51
Tab. (10)	Association of SVR 12 with baseline lab results, Fib4 and demographic factors of studied patients.	59
Tab. (11)	Compression between patients who achieve SVR and who didn't regarding baseline lab results, Fib 4 and demographic factors of studied patients.	55

Tab. (12)	hematological adverse events due to treatment all over the follow up period	56
Tab. (13)	correlation between patients who had adverse effects and response to treatment at the 4 Th week	59
Tab. (14)	correlation between patients who had adverse effects and response to treatment at the 12 th week	58
Tab. (15)	correlation between patients who had adverse effects and response to treatment at the 24th week	57
Tab. (16)	Adverse effects frequency distribution between patients in the 1th week classified by CTCAE V3	64
Tab. (17)	Adverse effects frequency distribution between patients in the 2nd week classified by CTCAE V3.	61
Tab. (18)	Adverse effects frequency distribution between patients in the 4th week classified by CTCAE V3	69
Tab. (19)	Adverse effects frequency distribution between patients in the 8th week classified by CTCAE V3.	69
Tab. (20)	Adverse effects frequency distribution between patients in our study in the 12th week classified by CTCAE V3	60
Tab. (21)	Comparison between patients with anemia and those without at 4th week regarding base line lab, Demographic data, response to treatment and Fib 4.	65
Tab. (22)	Comparison between patients with leucopenia and those without at 4th week regarding base line lab, demographic data, response to treatment and Fib 4.	69
Tab. (23)	Comparison between patients with Neutropenia and those without at 4th week regarding base line lab, demographic data, response to treatment and Fib 4.	67

Tab. (24)	Comparison between patients with thrombocytopenia and those without at 4 the week regarding base line lab, demographic data, response to treatment and Fib 4.	91
Tab. (25)	Comparison between patients with anemia and those without at 12th week regarding base line lab, demographic data, response to treatment and Fib 4.	99
Tab. (26)	Comparison between patients with leucopenia and those without at 12th week regarding base line lab, demographic data, response to treatment and Fib 4.	99
Tab. (27)	Comparison between patients with neutropenia and those without at 12th week regarding base line lab, demographic data, response to treatment and Fib 4.	90
Tab. (28)	Comparison between patients with thrombocytopenia and those without at 12th week regarding base line lab, demographic data, response to treatment and Fib 4.	95
Tab. (29)	validity and determination of cut off points of Fib 4 using anemia as an adverse effect associated	96
Tab. (30)	validity and determination of cut off points of FIB 4 using leucopenia as an adverse effect associated	99
Tab. (31)	validity and determination of cut off points of FIB 4 using neutropenia as an adverse effect associated	98

Keywords

- Fib4
- Hematological adverse events of sofosbuvir
- Triple therapy

ABSTRACT

Chronic hepatitis C is a major cause of cirrhosis, end stage liver disease and hepatocellular carcinoma. The population of Egypt has a heavy burden with HCV. The primary aim of anti-HCV therapy is permanent eradication of the virus or a sustained viral response there by reducing the risk of progression to end-stage liver disease and improving quality of life.

In Egypt, Patients infected with HCV genotype 4 and are eligible to IFN therapy can be treated with a combination of weekly PEGylated IFN- α , daily weight-based ribavirin (1000 mg in patients <75 kg or 1200 mg in patients \geq 75 kg), and daily sofosbuvir (400 mg) for 12 weeks). However, these drugs together with HCV itself have been reported to cause multiple hematological side effects e.g. anemia, neutropenia and thrombocytopenia

It has been reported that hematologic adverse effects during treatment by Peg INF and RBV are more common in patients with more advanced degree of fibrosis, in addition fibrosis score may be used as Predictor of response of HCV infected patients to therapy.

Aim of the work:

Assessment of relation between degree of fibrosis assessed by Fib4 and both response to treatment and hematological adverse effects related to treatment.

CONCLUSION:

Our research found that there is no association of degree of fibrosis assessed by Fib4 and SVR, but hematological adverse effects e.g. anemia, leucopenia, and neutropenia were common in patients with high degree of fibrosis assessed by Fib4



Introduction



Introduction

Hepatitis C virus infection is a serious worldwide problem. According to the World Health Organization, An estimated 130–170 million people are infected with hepatitis C worldwide leading to significant morbidity, mortality, and financial burden on healthcare (**WHO, 2013**). Out of people who contract the infection, 75–85% will develop chronic infection, 60–70% will develop chronic liver disease, 5–20% will develop cirrhosis over the course of their chronic infection, and 1–5% will die of complications including hepatocellular carcinoma (HCC) (**Wise *et al.*, 2008**).

Hepatitis C virus (HCV) has a long and relatively symptom-free incubation period prior to causing serious illness. An estimated 65–75% of currently infected individuals are unaware of their infection. The consequences of these undiagnosed and untreated chronic infections are expected to be staggering as this population ages with predictive models suggesting a two-fold increase in HCV-related deaths in the next few years (**Ly *et al.*, 2012**) and, without intervention, a four-fold rise in the incidence of end-stage liver disease related to hepatitis C within the next 20 years (**Rein *et al.*, 2011**).

Egypt has the largest epidemic of hepatitis C virus in the world (**WHO. 2011**). Egyptian Demographic Health Survey [EDHS] tested a representative sample of the entire country for HCV antibody. The sample included both urban and rural populations and included all 27 governorates of Egypt. Over 11,000 individuals were tested. The overall prevalence positive for antibody to HCV was 14.7 % (**El-Zanaty *et al.*, 2009**).